The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine

被引：0
|
作者：
Papageorgiou, Sotirios
Kontos, Christos K.
Tsiambalis, Thomas
Vyniou, Athina
Symeonidis, Argiris
Galanopoulos, Athanasios
Kotsianidis, Ioannis
Pappa, Vassiliki
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4252
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Azacitidine therapy in high-risk myelodysplastic syndromes (MDS): A single centre experience
    Improta, S.
    Gagliardi, A.
    Villa, M. R.
    Della Cioppa, P.
    Esposito, M.
    Izzo, G. Nitrato
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2013, 37 : S152 - S152
  • [42] HEMATOLOGIC RESPONSE TO AN ALTERNATIVE DOSING SCHEDULE OF AZACITIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Finelli, C.
    Clissa, C.
    y Follo, M.
    Curti, A.
    Paolini, S.
    Papayannidis, C.
    Testoni, N.
    Ottaviani, E.
    Parisi, S.
    Martinelli, G.
    Cocco, L.
    Baccarani, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 560 - 560
  • [43] SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE
    Stringer, R.
    Rider, D. T.
    Newman, D. J.
    Grace, D. R.
    HAEMATOLOGICA, 2015, 100 : 725 - 726
  • [44] Monosomal karyotype of chromosome 5/7 was an independent poor prognostic factor for Chinese myelodysplastic syndrome patients
    Zhang, Tongtong
    Xu, Yang
    Pan, Jinlan
    Qiu, Huiying
    Wu, Depei
    Chen, Suning
    Sun, Aining
    CANCER GENETICS, 2016, 209 (09) : 423 - 429
  • [45] Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
    Itzykson, Raphael
    Thepot, Sylvain
    Quesnel, Bruno
    Dreyfus, Francois
    Beyne-Rauzy, Odile
    Turlure, Pascal
    Vey, Norbert
    Recher, Christian
    Dartigeas, Caroline
    Legros, Laurence
    Delaunay, Jacques
    Salanoubat, Celia
    Visanica, Sorin
    Stamatoullas, Aspasia
    Isnard, Francoise
    Marfaing-Koka, Anne
    de Botton, Stephane
    Chelghoum, Youcef
    Taksin, Anne-Laure
    Plantier, Isabelle
    Ame, Shanti
    Boehrer, Simone
    Gardin, Claude
    Beach, C. L.
    Ades, Lionel
    Fenaux, Pierre
    BLOOD, 2011, 117 (02) : 403 - 411
  • [46] A PROGNOSTIC SCORING MODEL FOR PATIENTS TREATED WITH AZACITIDINE FOR MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIAS
    Sato, K.
    Inamura, J.
    Tsukada, N.
    Sato, K.
    Hosoki, T.
    HAEMATOLOGICA, 2016, 101 : 503 - 503
  • [47] Valproic acid at therapeutic plasma levels may increase 5-azacitidine efficacy in higher risk myelodysplastic syndromes
    Voso, M.
    Santini, V.
    Finelli, C.
    Musto, P.
    Pogliani, E.
    Di Tucci, A.
    Alimena, G.
    Buccisano, F.
    Cortellezi, A.
    Petti, M.
    Zini, G.
    Fabiani, E.
    Fazi, P.
    Piciocchi, A.
    Leone, G.
    LEUKEMIA RESEARCH, 2009, 33 : S139 - S140
  • [48] Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Borate, Uma
    Jacoby, Meagan A.
    Nowak, Daniel
    Baer, Maria R.
    Peterlin, Pierre
    Chyla, Brenda
    Wang, Huipei
    Ku, Grace
    Hoffman, David
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    BLOOD, 2025, 145 (11) : 1126 - 1135
  • [49] Intensive therapy for high-risk myelodysplastic syndromes and the biological significance of karyotype abnormalities
    Hiddemann, W
    Jahns-Streubel, G
    Verbeek, W
    Wörmann, B
    Haase, D
    Schoch, C
    LEUKEMIA RESEARCH, 1998, 22 : S23 - S26
  • [50] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Villa, M. R.
    Gagliardi, A.
    Della Cioppa, P.
    Esposito, M.
    Lucania, A.
    Izzo, G. Nitrato
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2016, 101 : S120 - S121
12345